Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

onCDI has become a significant medical problem in hospitals, long-term care facilities, and in the community.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), advanced age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. Increasing incidence, higher treatment failures and recurrence with current therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of C. difficile. The narrow-spectrum profile of fidaxomicin may eradicate C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics to treat CDI, metronidazole and vancomycin, disrupt the flora. Fidaxomicin may facilitate the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discoverin
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Today BioSpace , the leading life sciences employment ... spotlighting the life sciences community in Illinois , ... , Michigan , Minnesota , ... Ohio and Wisconsin . BioMidwest ... all job postings on BioSpace originating in this region in 2013. The ...
(Date:7/31/2014)... to see through organs and even the entire body ... fine-grained cellular structures has been a long-time dream of ... July 31st in the journal Cell has ... for making opaque organs, bodies, and human tissue biopsies ... The protocols could pave the way for a better ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Quantum Dots Market - Global ... - 2023," the market was valued at USD 88.5 ... 8,246.8 million by 2023, growing at a CAGR of ... full Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
(Date:7/31/2014)... 2014 According to a new ... Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ... Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry ... 2019," the global electrodes market for medical devices was ... estimated to reach a market worth USD 1,451.2 million ...
Breaking Biology Technology:Midwest Biotech Leaders Featured On BioSpace Map 2See-through organs and bodies will accelerate biomedical discoveries 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6
... 17 /PRNewswire/ - Norgen Biotek, an innovative Canadian ... for nucleic acids and protein purification, today announced ... A/S (NASDAQ OMX Copenhagen: "EXQ") to supply RNA ... Exiqon A/S is a Denmark-based company active in ...
... The pro bono healthcare injury prevention website ... that its newly instituted Safe Lifting Leadership Award ... of La Crosse, Wisconsin. The award was given ... safe patient handling, safe lifting, and caregiver injury ...
... Scheduled for Thursday, March 19, 2009 at 11:00 AM ... Milestone Scientific Inc. (OTC Bulletin Board: MLSS), ... that it intends to file its 2008 year-end results ... the U.S. Securities & Exchange Commission on Tuesday, March ...
Cached Biology Technology:Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 2Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 3Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 4Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 2Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 3Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 2Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 3
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... the roughly 156,000 gas stations across the United ... of underground gas storage tankscorrosion that could result ... source of drinking water. In recent years, field ... corroding gas storage tank components such as sump ... of gasoline-ethanol blends and the presence of bacteria, ...
(Date:7/31/2014)... people make a rational choice to be liberal or ... it a matter of genetics?, Two political scientists from ... University say that neither conscious decision-making nor parental upbringing ... lean right. , A growing body of evidence shows ... core of political differences, the researchers say in the ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3NIST corrosion lab tests suggest need for underground gas tank retrofits 2Scientists find growing consensus: Political attitudes derive from body and mind 2
... reefs in the Indo-Pacific region, including the Great Barrier ... counterparts, leading marine scientists said today. Dr George ... of Excellence for Coral Reef Studies and The University ... in Cairns that coral reefs in the Indo-Pacific Ocean ...
... centuries, people made wine by stomping grapes with their bare feet. ... University of British Columbia,s Wine Research Centre. , Have you ever ... wine? Has one glass of Merlot or Shiraz resulted in a ... percent of people who are allergic to compounds that are in ...
... group at the Smithsonian Tropical Research Institute in Panama ... Florida Museum of Natural History discovered a new species ... in what is now northwestern South America. The team,s ... new turtle species is named Puentemys mushaisaensis because it ...
Cached Biology News:Our coral reefs: In trouble - but tougher than we thought 2Winemaking goes high-tech at the University of British Columbia 2
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... Bio-Beads SM-2 adsorbents are macroporous polystyrene beads ... high surface area for adsorbing organics of ... solutions. The beads are useful for the ... agents; for example, the removal of detergents ...
... Anti-Mi-2 Immunogen : Fusion ... residues 474-970 of human Mi-2 ... 0.105M NaCl, 0.035% sodium azide, ... routinely evaluated by immunoblot on ...
Biology Products: